Demographic Outcomes, and Health Care Resources in Newly Diagnosed Non Valvular AF Patients
Summary
1. To describe the patterns of care of newly diagnosed patients with NVAF vs VAF in the first-line, second-line and beyond second line setting, including, treatment plan, regimen, dosing, duration of treatment, and reason for interruption and termination along with treatment switching at any point of treatment, regardless if the patients are considered of first line, second line or further within the treatments.
2. To describe the clinical outcomes (stroke/systemic embolism, bleeding complications, as well as cause-specific and all-cause mortality) with NVAF vs VAF.
3. To describe the values and distribution of International normalized ratio (INR) in patients who received VKAs and to assess the influence of Time in therapeutic range (TTR) and INR history on clinical outcomes (stroke/systemic embolism, bleeding complications) with NVAF vs VAF.
4. To evaluate AF-related healthcare resource utilization and direct costs associated with the management of AF patients with NVAF vs VAF.
and To describe the baseline clinical and demographic characteristics as well as risk factors among patients newly diagnosed with NVAF versus VAF.
Study Design
Conditions
Non Valvular AF ,AF
Location
Assiut university
Assiut
Egypt
71511
Status
Recruiting
Source
Assiut University
Results (where available)
Links
- Source: http://clinicaltrials.gov/show/NCT04110197
- ClinicalTrials.gov processed this data on October 04, 2019
Published on BioPortfolio: 2019-10-07T08:56:59-0400
Clinical Trials
Valvular Heart Disease Registry
Patients undergoing transcatheter valvular interventions will be prospectively included into the present registry. Baseline, procedural and follow-up data will be collected and analyzed to...
Valvular Heart Disease Registry Study in Second Affiliated Hospital of ZheJiang University
Valvular heart disease (VHD) is becoming more and more frequent with the aging, which has brought a heavy burden to the world. However, the prevalence and prognosis of valvular heart disea...
Pharmacological Postconditioning During the Aortic Valvular Surgery
Primary objective: To evaluate the efficacy of the cyclosporin A administration to induce a cardioprotection during the valvular surgery.
Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation
The primary objectives of this study are to compare the risk of major bleeding and stroke/systemic embolism (SE) events among oral anticoagulant (OAC)-naïve non-valvular atrial fibrillati...
Benefits of ICD for the Primary Prevention in Patients With Valvular Cardiomyopathy
The prevalence of valvular heart disease is on the rise along with the aging society and the generalization of echocardiography. Furthermore, the rheumatic valvular heart disease is much m...
PubMed Articles
The acute valvular dysfunction is a rapidly growing and critical condition in the intensive care unit with a cardiogenic shock as the most serious clinical entity. There are clearly defined guidelines...
Atrial fibrillation (AF) is the most common arrhythmia. Patients with valvular heart disease (VHD) frequently have AF. Growing evidence demonstrates that a specifically altered pattern of microRNA (mi...
Systolic Blood Pressure and Risk of Valvular Heart Disease: A Mendelian Randomization Study.
Modifiable risk factors for valvular heart disease remain largely unknown, which limits prevention and treatment.
Valvular aortic stenosis in three cats.
Aortic stenosis affects 0.028% of cats in a shelter population, with valvular aortic stenosis compromising almost half of these cases. Of congenital heart diseases reported in cats, aortic stenosis is...
To describe the renal function of individuals newly diagnosed with non-valvular atrial fibrillation (NVAF) in England, and describe how oral anticoagulant (OAC) treatment varies according to renal fun...
Medical and Biotech [MESH] Definitions
Rivaroxaban
A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.
Cardiac Output, Low
A state of subnormal or depressed cardiac output at rest or during stress. It is a characteristic of CARDIOVASCULAR DISEASES, including congenital, valvular, rheumatic, hypertensive, coronary, and cardiomyopathic. The serious form of low cardiac output is characterized by marked reduction in STROKE VOLUME, and systemic vasoconstriction resulting in cold, pale, and sometimes cyanotic extremities.
More From BioPortfolio on "Demographic Outcomes, and Health Care Resources in Newly Diagnosed Non Valvular AF Patients"
Quick Links
Advanced Search |
Login |
Subscribe |
RSS 
BioPortfolio Twitter Channels (200+ Accounts)
LinkedIn